All News

pediatric.kid_.jpg

ACR22 Presents New Data on JIA Clinical Remission with Combo DMARDSs

EurekAlert!

New research being presented this week at ACR Convergence 2022, demonstrated that polyarticular juvenile idiopathic arthritis patients were more likely to achieve clinical remission with a combination of conventional and biologic DMARDs compared with other consensus treatment plans by the Childhood Arthritis and Rheumatology Research Alliance (CARRA).

Read Article
exercise,group

ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment

ACR

On Sunday Nov. 13, 2022, at ACR Convergence 2022 meeting, the ACR will present a new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis.

Read Article
infection pneumonia

Opportunistic Infections with JAK inhibitors in RA

Jack Cush, MD

Winthrop and colleagues have reviewd the occurrence of opportunistic infections (OIs) associated with the use of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), showing that Herpez zoster (HZ) was the most common OI reported with JAK inhibitors in clinical trials, althou

Read Article
TB.EMimage.CDC_.jpg

2022 EULAR Recommendations for Screening and Prophylaxis of Chronic and Opportunistic Infections

Jack Cush, MD

A EULAR Task force has developed recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD).

Read Article
undifferentiated,arthritis,early,RA

Undiagnosed RA During the Pandemic

EurekAlert!

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.

Read Article
warning, caution

EMA Crack Down on JAK Inhibitors

Jack Cush, MD

The European Medicines Agency’s (EMA's) safety committee (PRAC) has issued a recommendation that the use of oral JAK inhibitors (tofacitinib, baricitinib, upadacitinib and filgotinib) be limited to certain at-risk patients unless no other suitable treatment alternatives are available.

Read Article
RheumNow Podcast square

Infections & Lupus (10.28.2022)

Jack Cush, MD

Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill. 

Read Article
biosimilars2.jpg

Growing Confidence in Biosimilars?

MediaSource

Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends

Read Article
#ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment https://t.co/FI5k6LIKrO https://t.co/I0F1wJNBDc

Links:

Dr. John Cush RheumNow ( View Tweet)
Opportunistic Infections with JAK inhibitors in RA Winthrop and colleagues have reviewed the occurrence of OIs associated with the use of JAK inhibitors in patients with RA, showing that Herpez zoster (HZ) was the most common OI reported. https://t.co/CtFcnHiWKS https://t.co/qKU51vLxaP

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Seropositive Arthralgia (abstract #1604) 42 yr old woman with +RF and Arthralgias only. How to treat? https://t.co/MgPFHa0CAd https://t.co/Aqlrc6rOSt

Links:

Dr. John Cush RheumNow ( View Tweet)
Undiagnosed RA During the Pandemic The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests. https://t.co/qEcEF8ukxm https://t.co/PcXAxrjT24

Links:

Dr. John Cush RheumNow ( View Tweet)
"I can't wait to see how the new format works: the poster hall, the SPARK talks, and to see a whole lot of people in person!" Follow Dr. David Liew, @drdavidliew, for real-time #ACR22 coverage! https://t.co/RBbLyqrBNT
Dr. John Cush RheumNow ( View Tweet)
GSK announced they will halt development of Otilimab (anti-GM-CSF mAb) to treat #RA; decisioin based on negative results from phase 3 ContRAst-3 study, that failed to meet ACR20 primary endpoint in RA pts who failed bDMARDs or JAKi https://t.co/cDqcYKOjSa https://t.co/7rB4TYsWnZ

Links:

Dr. John Cush RheumNow ( View Tweet)
New ACR/EULAR Guideline Expands RA Remission Definition Newly released guidance for defining remission in RA is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes. https://t.co/ZZN3kAGW8F https://t.co/iaYUvxYHMq

Links:

Dr. John Cush RheumNow ( View Tweet)
Mayo Clinic Biobank matched case-control study (1:3) of 212 incident RA cases Active work physical activity lowered risk of RA (aOR 3.00), while 3-5 servings high-fat foods, fruits/vegetables lowered risk (OR 0.45; OR 0.54). https://t.co/PW6XRxzcDi https://t.co/wXnu9T55Yb

Links:

Dr. John Cush RheumNow ( View Tweet)
TNF inhibitors Dont Increase Cancer Risk! 4592 RA pts:TNFi Rx (2296) vs matched DMARD Rx (2296) pts. TNFi had a lower cancer risk than DMARD Rx (IR 6.5 vs. 15.6 /1000PYs]). TNFi had Lower HR GI CA (0.432), breast CA (0.146), GU CA (0.220) https://t.co/mf1g0LwjXR
Dr. John Cush RheumNow ( View Tweet)
Celebrating my 10,000 followers on TikTok. @Rheum101 is where I make videos teaching rheumatology to the general public in 3 min bites. Topics include #SLE #Steroids #RA #ANA #RheumLabs #DMARDS #biologics #JAKi #osteoporosis #PsA and more #RheumEducation #NotMedicalAdvice https://t.co/WEXspp5v28
TheDaoIndex KDAO2011 ( View Tweet)
RA is an independent risk factor for Thyroid Dz & AITD. Study of 250 RA & 248 non-inflammatory RMD controls. RA had more abnl TFTs (34% v 19%; OR 2.2), Overt hypothyroidism, Anti-TPO Abs, & AITD (21.5% vs 9%; OR 2.8). https://t.co/lRvY4VGkUc https://t.co/ibUqPiD9Bv

Links:

Dr. John Cush RheumNow ( View Tweet)
Will we see you there? #ACR2022 What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×